
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CTH120
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain
Deal Size : Inapplicable
Deal Type : Inapplicable
CTH120 First-in-Human Study: Single and Multiple Ascending Doses and Potential Food Interaction
Details : CTH120 is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Fragile X Syndrome.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 01, 2024
Lead Product(s) : CTH120
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Hospital del Mar Research Institute (IMIM) | Adknoma | Ministry of Science and Innovation, Spain
Deal Size : Inapplicable
Deal Type : Inapplicable
